Table 3

Association between MetS and brain MRI in participants with symptomatic arterial disease without diabetes (n = 975)

Global brain atrophy (BPF, %)
B (95% CI)Subcortical brain atrophy (VF, %)
B (95% CI)ln WMH (%)
B (95% CI)LIs (n = 162)
OR (95% CI)Non-LIs
(n = 156)
OR (95% CI)
MetS
 Model 1−0.4 (−0.7, −0.1)0.05 (−0.07, 0.17)−0.01 (−0.15, 0.13)0.79 (0.53, 1.18)1.38 (0.95, 2.00)
 Model 2−0.42 (−0.70, −0.13)0.04 (−0.08, 0.15)−0.03 (−0.17, 0.11)0.71 (0.46, 1.10)1.48 (0.96, 2.27)
Individual componentsa
 Impaired glucose metabolismb−0.27 (−0.59, 0.05)0.002 (−0.13, 0.13)−0.06 (−0.21, 0.09)0.57 (0.36, 0.91)*0.85 (0.55, 1.31)
 Elevated blood pressure−0.20 (−0.54, 0.14)0.09 (−0.05, 0.23)0.10 (−0.05, 0.26)3.00 (1.62, 5.55)2.75 (1.52, 5.00)
 Low HDL cholesterol0.03 (−0.26, 0.32)−0.08 (−0.20, 0.04)0.06 (−0.08, 0.20)0.67 (0.41, 1.01)0.94 (0.64, 1.38)
 Elevated triglycerides−0.32 (−0.60, −0.04)*0.04 (−0.07, 0.16)−0.04 (−0.17, 0.09)1.01 (0.70, 1.47)1.26 (0.88, 1.81)
 Abdominal obesity−0.38 (−0.68, −0.07)*0.09 (−0.03, 0.21)0.06 (−0.08, 0.20)1.04 (0.70, 1.55)1.12 (0.76, 1.65)
  • Non-LIs include cortical, large subcortical, or infratentorial infarcts. Model 1 is adjusted for age and sex. Model 2 is as model 1 but additionally adjusted for current smoking and alcohol intake, IMT, and history of cerebrovascular disease.

  • aAdjusted for age and sex.

  • bIncludes patients with a glucose level >6.1 and <7.0 mmol/L.

  • *P < 0.05;

  • P < 0.01.